Target intelligence / Profile preview

Maprotiline at Histamine H1, Adrenergic α1, and Muscarinic receptors

Molecular classification
G protein-coupled receptor
01

Overview

The listed targets—Histamine H1 receptor, Alpha-1 adrenergic receptor, and Muscarinic acetylcholine receptor—are all G protein-coupled receptors present in the central and peripheral nervous system. Maprotiline, a tetracyclic antidepressant, produces its therapeutic and side effects largely through antagonism at these receptors, alongside potent inhibition of norepinephrine reuptake. This multi-modal profile explains its antidepressant, anxiolytic, sedative, and sympatholytic properties, as well as typical TCA-type side effects including sedation, anticholinergic symptoms, and potential cardiovascular impacts[1][3][7][9].

Other names
H1RHRH1α1-ARADRA1Muscarinic receptormAChR
02

Mechanism of action

Histamine H1 receptor: Antagonism (inhibition of histaminergic activity; sedative, anti-allergy effects); Alpha-1 adrenergic receptor: Antagonism (reduces vasoconstrictive effects; may lower blood pressure, cause orthostatic hypotension); Muscarinic acetylcholine receptor: Weak antagonism (may cause anticholinergic effects such as dry mouth, blurred vision)

03

Biological functions

Signal transductionNeurotransmitter modulationRegulation of vasomotor tone (adrenergic receptor)Mediation of allergic response (H1)Autonomic nervous system regulation (muscarinic)
04

Disease associations

Neuropsychiatric disorders (depression, anxiety)Allergic diseases (H1 receptor: allergy, rhinitis)Cardiovascular disease (α1-adrenergic receptor)Side effect profiles relate to sedation, anticholinergic burden, orthostatic hypotension
05

Safety considerations

Sedation (strong H1 antagonism)Anticholinergic effects (muscarinic antagonism; less than other TCAs but present)Orthostatic hypotension (α1 adrenergic antagonism)Arrhythmias (risk of hERG channel inhibition in high doses)Skin rashes (incidence notably increased compared to other antidepressants)
06

Interacting drugs

Maprotiline

4 more in the full profile.

07

Biomarkers

None established for direct patient selection for these receptors in the context of maprotiline therapy; generally not used as predictive biomarkers for efficacy.

Beyond the preview

Go deeper on Maprotiline at Histamine H1, Adrenergic α1, and Muscarinic receptors.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Maprotiline at Histamine H1, Adrenergic α1, and Muscarinic receptors.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call